Parsa Mohebi Hair Restoration launches human study of verteporfin in FUE healing

Parsa Mohebi Hair Restoration has launched Project V, a controlled human study of locally administered verteporfin in hair transplant donor sites. The trial will compare treated and untreated areas in the same patient to assess scarring, hair density, healing and safety, with enrollment expected after study setup is complete.

Why it matters: - Project V could add controlled human data to a small evidence base on verteporfin and hair restoration. - The study is aimed at a practical question: whether donor tissue healing after follicular unit extraction can be improved in a measurable, reproducible way. - If regenerative healing proves useful, the implications could extend to donor management, scarring and the long-term limits of hair transplantation.

What happened: - Parsa Mohebi Hair Restoration announced Project V on Sept. 2, 2026. - The study will test whether locally administered verteporfin affects healing after follicular unit extraction hair transplantation. - The trial will compare verteporfin-treated and untreated donor areas within the same patient. - Patient enrollment is expected to begin after study setup is completed.

The details: - Researchers will evaluate hair density, donor-site appearance, scarring and fibrosis-related changes, healing characteristics, local safety and adverse reactions. - Participants will be tracked with standardized clinical evaluations and photography. - The within-patient design is meant to reduce variability tied to age, hair characteristics, skin biology and healing response. - The project is being developed through pharmaceutical sourcing and clinical preparation. - Parsa Mohebi Hair Restoration said the study is not designed to assume verteporfin regenerates hair follicles or prevents scarring. - The company said the goal is to determine whether a clinically meaningful difference exists between treated and untreated areas. - Parsa Mohebi Hair Restoration said updates on enrollment, progress and findings will be published as they become available.

Between the lines: - Verteporfin is FDA-approved for certain eye conditions when used with photodynamic therapy, but its use in wound healing, scar reduction, hair regeneration or hair transplantation is investigational and off-label. - Interest in the drug has grown after preclinical work linked YAP-related mechanotransduction and fibroblast activation to scar formation. - Earlier studies found verteporfin-treated wounds showed reduced fibrosis and regenerative features in animal models. - More recent preclinical research published in Science Translational Medicine reported that a single verteporfin treatment after wounding prevented scarring and promoted regenerative healing. - Those findings matter for hair transplant donor sites because FUE creates thousands of small wounds in scalp tissue that contains healthy follicles. - Human results are still unproven, and animal data cannot be assumed to translate to the human scalp. - Dr. Parsa Mohebi said the study is intended to investigate the possibility scientifically, not make claims ahead of evidence.

What's next: - Project V will move forward once study setup is finished and enrollment opens. - Researchers will look for whether any treatment effect remains measurable over time. - The practice said future updates will cover enrollment, study progress and eventual findings. - If the data are positive, the work could inform larger studies on regenerative donor healing in hair transplantation.

The bottom line: - Project V is a controlled attempt to answer a narrow but important question: can verteporfin improve human donor-site healing after FUE, or not?